CytomX Therapeutics (CTMX)
(Delayed Data from NSDQ)
$1.51 USD
+0.10 (7.09%)
Updated Jul 16, 2024 04:00 PM ET
After-Market: $1.50 -0.01 (-0.66%) 7:58 PM ET
2-Buy of 5 2
C Value B Growth F Momentum C VGM
Brokerage Reports
CytomX Therapeutics, Inc. [CTMX]
Reports for Purchase
Showing records 81 - 100 ( 152 total )
Company: CytomX Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
CX-2029 Data Trigger Milestone Payment; Pipeline Update; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: CytomX Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Astellas Pays up for Bispecifics; Upgrading to OUTPERFORM
Provider: WEDBUSH SECURITIES INC.
Analyst: DRISCOLL R
Company: CytomX Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
CytomX Inks Astellas Agreement on Probody Bispecifics; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: CytomX Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
2019 Financial Results Reported; Multiple 2020 Data Readouts; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: CytomX Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Q4 Financials; Platform Progresses with Data-Rich Year Ahead
Provider: WEDBUSH SECURITIES INC.
Analyst: DRISCOLL R
Company: CytomX Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
BMS-986249 Plus Opdivo to Be Tested in Melanoma; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: CytomX Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
CX-2009 Targeting HR+, HER2 Metastatic Breast Cancer First; Upcoming 2020 Catalysts; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: CytomX Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
CX-2009 Advanced into HR+/HER2- Breast Cancer; Pipeline Update
Provider: WEDBUSH SECURITIES INC.
Analyst: DRISCOLL R
Company: CytomX Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: CytomX Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Q3 Financials; Downgrading to NEUTRAL as Development Paths Remain Unclear
Provider: WEDBUSH SECURITIES INC.
Analyst: DRISCOLL R
Company: CytomX Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
3Q19 Financials Reported; Reiterate Buy and Reducing PT to $14
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: CytomX Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: CytomX Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Q2 Financials; Multiple Strategic Updates Expected in 2H19
Provider: WEDBUSH SECURITIES INC.
Analyst: DRISCOLL R
Company: CytomX Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: CytomX Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
HEALTHCARE - The Week Ahead in Life Sciences
Provider: WEDBUSH SECURITIES INC.
Analyst: Research Department
Company: CytomX Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
AbbVie''s Selection of a Second Target Ameliorates Probody Validation, in Our View; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: CytomX Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Biotechnology - ASCO Roundup for Covered Companies
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: CytomX Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
CX-072 ASCO Update Further Affirms Probody Platform Profile Advantage; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: CytomX Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
The Week Ahead in Life Sciences
Provider: WEDBUSH SECURITIES INC.
Company: CytomX Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Biotechnology- ASCO Abstract Roundup for Covered Companies
Provider: WEDBUSH SECURITIES INC.